` BSLN (Basilea Pharmaceutica AG) vs Swiss Market Index Comparison - Alpha Spread

BSLN
vs
Swiss Market Index

Over the past 12 months, BSLN has outperformed Swiss Market Index, delivering a return of 3% compared to the Swiss Market Index's 2% growth.

Stocks Performance
BSLN vs Swiss Market Index

Loading
BSLN
Swiss Market Index
Add Stock

Performance Gap
BSLN vs Swiss Market Index

Loading
BSLN
Swiss Market Index
Difference
www.alphaspread.com

Performance By Year
BSLN vs Swiss Market Index

Loading
BSLN
Swiss Market Index
Add Stock

Competitors Performance
Basilea Pharmaceutica AG vs Peers

Swiss Market Index
BSLN
ABBV
AMGN
GILD
VRTX
Add Stock

Basilea Pharmaceutica AG
Glance View

Market Cap
545.8m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
59.87 CHF
Undervaluation 25%
Intrinsic Value
Price
Back to Top